{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:48:00Z","timestamp":1785700080064,"version":"3.56.0"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"Abstract<\/jats:title>\n \n Aim:<\/jats:title>\n In type 2 diabetes mellitus (T2DM), Metabolic dysfunction-associated steatotic liver disease (MASLD) is emerging as a significant health problem; however, the treatment options appear to be restricted despite an overlap between MASLD and diabetes. The present trial was conducted to investigate the efficacy of SGLT-2 inhibitor (dapagliflozin) in improving the metabolic and liver parameters in MASLD and type 2 diabetes.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n \n A 24-week randomized controlled trial evaluated the role of dapagliflozin (10 mg\/day) in MASLD and T2DM patients. 1:1 randomization was done into dapagliflozin plus standard care (\n n<\/jats:italic>\n = 34) or standard care alone (\n n<\/jats:italic>\n = 30). Changes in liver steatosis (Ultrasonography [USG]), fibrosis (fibroscan, fibrosis-4, and aspartate aminotransferase (AST)-to-platelet ratio index [APRI]), and biochemical markers were analyzed. Data were analyzed using SPSS, and\n P<\/jats:italic>\n < 0.05 was considered significant.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n At the 24-week follow-up, a significant reduction in AST (\n P<\/jats:italic>\n = 0.027) and alanine aminotransferase (\n P<\/jats:italic>\n = 0.002) levels was observed in the dapagliflozin group. Significant decline in triglycerides (\n P<\/jats:italic>\n = 0.020) and an increase in high-density lipoprotein cholesterol (\n P<\/jats:italic>\n = 0.001) were observed. No significant differences were observed in liver stiffness measurement, FIB4, and glycated hemoglobin levels; however, the APRI score declined significantly (\n P<\/jats:italic>\n = 0.038). The intervention group maintained a higher body mass index (\n P<\/jats:italic>\n = 0.037) but showed hepatic improvements. No adverse events were reported during the trial, and the drug was well-tolerated.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Dapagliflozin (SGLT-2 inhibitor) significantly reduces markers of dyslipidemia and liver injury in MASLD and type 2 diabetes patients, and this effect appears to be independent of weight loss. Results of a 24-week trial showed a decrease in inflammation; a longer-duration trial will establish significant improvement in hepatic fibrosis.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/aam.aam_298_26","type":"journal-article","created":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T07:00:10Z","timestamp":1784444410000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Dapagliflozin (Sodium-glucose Transport Protein 2 Inhibitor) on Liver Steatosis and Fibrosis in Subjects with Type 2 Diabetes Mellitus and Metabolic Dysfunction-associated Steatotic Liver Disease"],"prefix":"10.4103","author":[{"given":"Shariq","family":"Ayaz","sequence":"first","affiliation":[{"name":"Department of Medicine, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Haider Mehdi","family":"Husaini","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Rajiv Gandhi Centre of Diabetes and Endocrinology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah Mohammad Abbas","family":"Waseem","sequence":"additional","affiliation":[{"name":"Department of Physiology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,15]]},"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_298_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T18:57:28Z","timestamp":1785697048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_298_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":0,"URL":"https:\/\/doi.org\/10.4103\/aam.aam_298_26","relation":{},"ISSN":["1596-3519","0975-5764"],"issn-type":[{"value":"1596-3519","type":"print"},{"value":"0975-5764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"2026-03-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}